

Joint decision making **MAKING STRIDES** IN HEMOPHILIA CARE

Chaired by
Victor Blanchette, SCM, FRCP(C), FRCP

An educational symposium initiated, organized, and funded by Takeda

Join our experts who will discuss the tools and resources available to the multidisciplinary team to optimize joint health treatment in people with hemophilia A.

Tuesday, February 1, 2022

18:00–19:00 CET, virtual

<https://mcigroup.eventsair.com/eahad-2022>



Joint decision making
MAKING STRIDES
IN HEMOPHILIA CARE



We are pleased to invite you and your colleagues to our virtual symposium, which will consist of three on-demand presentations by international experts in the field of hematologic disorders, and a panel discussion moderated by our distinguished chair.

The symposium will be chaired by **Victor Blanchette**, who will provide an overview of the current standard of care in hemophilia A treatment, with a particular focus on joint health.

Sonata Šaulytė Trakymienė will then discuss how treatment can accommodate an individual's lifestyle choices and highlight the importance of considering pharmacokinetic parameters to protect joints. **Hortensia de la Corte-Rodríguez** to follow and provide insights into the use of point-of-care ultrasound to assess joint status and to guide treatment decisions. The symposium will conclude with a **panel discussion**, where our distinguished experts will explore concepts and approaches that enable collaboration of the multidisciplinary team and thereby optimize the management of treatment in people with hemophilia A.

Time (CET)	Session title	Speaker
18:00	Joint decision making Making strides in hemophilia care	Victor Blanchette The Hospital for Sick Children Toronto, Canada
18:10	Joint protection The peaks and troughs of clinical decision making	Sonata Šaulytė Trakymienė Vilnius University Children's Hospital Vilnius, Lithuania
18:27	Joint illumination The use of ultrasound to assess joint health	Hortensia de la Corte-Rodríguez La Paz University Hospital Madrid, Spain
18:44	Panel discussion: Joint management Towards integrated hemophilia care	All Moderator: Victor Blanchette

Available from February 1, 2022
<https://mcigroup.eventsair.com/eahad-2022>

The symposium is intended for healthcare professionals outside of the United States who are registered attendees of the EAHAD 2022 virtual congress only.



Global Code: VV-MEDMAT-52799. UK Code: C-APROM/GB/HG/0058.
Date of Preparation: December 2021.

This is a Takeda-sponsored educational symposium at the 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).



The UK ABPI Code of Practice categorizes any medical educational event developed by a pharmaceutical company during which that company's medicines are discussed, including this one, as a promotional event.

Rurioctog alfa pegol ▼ is subject to additional monitoring.

This will allow quick identification of new safety information. Adverse events should be reported to the Medicines and Healthcare products Regulatory Agency. Reporting forms and information can be found at: <https://yellowcard.mhra.gov.uk/>.

Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com.

Prescribing information for octocog alfa and rurioctog alfa pegol can be found [here](#).

The symposium is initiated, organized, and funded by Takeda. ©2022 Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda logo are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. All rights reserved. Takeda Pharmaceuticals International AG, Thurgauerstrasse 130, 8152 Glattpark-Opfikon, Switzerland.